Testing effectiveness (Phase 2)Study completedNCT00773838
What this trial is testing
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
Who this might be right for
Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC 143